Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease - Zhang, Y; Jiang, L; Wang, J (Cardiovasc Diabetol, 2022)